Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Type
- Observational
- Design
- Observational Model: Case-OnlyTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
* Part 1, Prospective Collection of Fresh Tumor-Distant Normal Pairs The investigators will prospectively collect 25 pairs of fresh HNSCC tumor-distant normal mucosal tissue. * Part 2, Retrospective Molecular Epidemiology Study of the Association of miRs with Therapeutic Response and Prognosis in HN...
* Part 1, Prospective Collection of Fresh Tumor-Distant Normal Pairs The investigators will prospectively collect 25 pairs of fresh HNSCC tumor-distant normal mucosal tissue. * Part 2, Retrospective Molecular Epidemiology Study of the Association of miRs with Therapeutic Response and Prognosis in HNSCC. The investigators will comprehensively test the association between miR expression and miR promoter methylation, and the response to therapy and survival in all cases of surgical HPV-negative HNSCC at UNMH collected after 1990. Lip and nonkeratinizing nasopharyngeal cases will be excluded as these are etiologically distinct and related to cutaneous SCC or to EB virus infection, respectively. No cases will be excluded due to gender, age, race or ethnicity.
Tracking Information
- NCT #
- NCT03953443
- Collaborators
- Lovelace Respiratory Research Institute
- Investigators
- Principal Investigator: Garth Olson, MD University of New Mexico Comprehensive Cancer Center
Get Well Soon